XELEVIA - VELMETIA

XELEVIA: Inclusion on the list of medicines refundable by National Health Insurance (B/28) and approved for hospital use (B/28 and B/50) in the following extensions of indication: “For patients with type 2 diabetes mellitus, XELEVIA is indicated to improve glycaemic control: as monotherapy, in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance and as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control”. VELMETIA: Inclusion on the list of medicines refundable by National Health Insurance and approved for hospital use (B/56) in the following extension of indication: “VELMETIA is indicated as an adjunct to diet and exercise to improve glycaemic control in type 2 diabetic patients as add-on to insulin (triple therapy) when stable dose of insulin and metformin alone do not provide adequate glycaemic control”.